CEPI Deal History & Licensing Activity
CEPI is a life sciences. Over the past three years, CEPI has been involved in 2 licensing and acquisition transactions, with a primary focus on mRNA (4 deals). The company currently has 1 active clinical trial, primarily in Infectious Disease.
Deals (12mo)
1
Active Trials
1
Top Modality
mRNA
Focus Area
Infectious Disease
CEPI Recent Deal Activity
Licensing, acquisition, and partnership transactions involving CEPI in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| mRNA-1018 | Moderna | mRNA | Phase 3 | collaboration | Dec 2025 |
| mRNA-1018 | Moderna | mRNA | Phase 3 | collaboration | Dec 2025 |
CEPI Pipeline Focus
Therapeutic areas and modalities where CEPI is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
CEPI Strategic Signals
Key indicators of CEPI's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
CEPI Clinical Pipeline
CEPI has 1 active clinical trial across 1 development phase.
1
Phase 3
See How Your Asset Matches CEPI's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About CEPI Licensing & Deal Activity
CEPI is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, CEPI ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for CEPI include Infectious Disease (4 deals and trials). In terms of modality, CEPI has shown particular interest in mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for CEPI and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against CEPI's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.